Table 2

 Doses of rituximab and glucocortiocids in three randomised controlled clinical trials

StudyRituximab doseIntravenous glucocorticoidsOral Glucocorticoids
DMARD, disease-modifying antirheumatic drug; MP, methylprednisolone; P, prednisone.
*Edwards et al’s14 study comprised a population of patients with active disease despite traditional treatment with DMARDs. In Emery et al’s13 study, two thirds of the patients had active disease despite traditional treatment with DMARDs, whereas one third had active disease despite treatment with TNF inhibitors. In Cohen et al’s12 study, all patients had active disease despite treatment with TNF inhibitors.
Edwards et al142×1000 mg2×100 mg MP on days 1 and 1560 mg P, days 2, 4–7+30 mg P, days 8–14
Emery et al132×1000 mg or 2×500 mg(1) 0(1) 0
(2) 2×100 mg MP*(2) 0
(3) 2×100 mg MP*(3) 60 mg P on days 2–7+30 mg P on days 8–14
No marked difference in efficacy between the two rituximab dosesPremedication markedly reduced infusion-related adverse events after the first infusion; no appreciable difference in efficacyOral P did not influence infusion reactions to the second infusion
Cohen et al122×1000 mg2×100 mg MP*60 mg P on days 2–7+30 mg P on days 8–14